XNAS
LVTX
Market cap33mUSD
May 02, Last price
1.28USD
1D
3.23%
1Q
30.61%
IPO
-90.86%
Name
LAVA Therapeutics NV
Chart & Performance
P/E
—
P/S
2.81
EPS
—
Div Yield, %
—
Shrs. gr., 5y
7.82%
Rev. gr., 5y
%
Revenues
12m
+77.01%
Net income
-25m
L-40.17%
CFO
-20m
L-49.85%
Earnings
May 19, 2025
Profile
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-051, which is in Phase 1/2a clinical trial for blood cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia; and LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is also developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 and LAVA-1278, which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use. The company was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | ||||||
Revenues | 11,982 77.01% | 6,769 -65.09% | 19,391 262.45% | |||
Cost of revenue | 41,675 | 50,022 | 54,229 | |||
Unusual Expense (Income) | ||||||
NOPBT | (29,693) | (43,253) | (34,838) | |||
NOPBT Margin | ||||||
Operating Taxes | (630) | 279 | 249 | |||
Tax Rate | ||||||
NOPAT | (29,063) | (43,532) | (35,087) | |||
Net income | (25,114) -40.17% | (41,974) 31.55% | (31,907) -24.67% | |||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | ||||||
BB yield | ||||||
| Debt | ||||||
Debt current | 315 | 5,722 | 5,019 | |||
Long-term debt | 555 | 1,622 | 1,241 | |||
Deferred revenue | 35,000 | 35,000 | ||||
Other long-term liabilities | 34,920 | 4,732 | ||||
Net debt | (75,706) | (88,227) | (126,608) | |||
| Cash flow | ||||||
Cash from operating activities | (19,544) | (38,972) | 4,043 | |||
CAPEX | (23) | (730) | (587) | |||
Cash from investing activities | 12,475 | (17,635) | 9,346 | |||
Cash from financing activities | (569) | (571) | 283 | |||
FCF | (28,012) | (43,943) | (34,259) | |||
| Balance | ||||||
Cash | 76,576 | 95,571 | 132,868 | |||
Long term investments | ||||||
Excess cash | 75,977 | 95,233 | 131,898 | |||
Stockholders' equity | (183,911) | (155,251) | (108,384) | |||
Invested Capital | 247,051 | 247,742 | 239,561 | |||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 26,834 | 26,733 | 25,924 | |||
Price | 0.95 -39.81% | 1.58 -54.86% | 3.50 -36.36% | |||
Market cap | 25,520 -39.58% | 42,237 -53.45% | 90,734 -16.50% | |||
EV | (50,186) | (45,990) | (35,874) | |||
EBITDA | (29,226) | (41,975) | (34,057) | |||
EV/EBITDA | 1.72 | 1.10 | 1.05 | |||
Interest | 515 | |||||
Interest/NOPBT | ||||||